Zentalis Pharmaceuticals (ZNTL) Net Cash Flow (2019 - 2026)

Zentalis Pharmaceuticals has reported Net Cash Flow for 8 years, with the latest figure at -$4.1 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 150.64% year-over-year to -$4.1 million; the trailing twelve-month figure through Mar 2026 stood at -$10.0 million (down 334.77% YoY), and the FY2025 full-year result was $2.1 million, down 63.95% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$4.1 million, down from -$3.1 million in the prior quarter.
• The five-year high for Net Cash Flow was $230.3 million in Q2 2023, with the low at -$155.8 million in Q3 2023.
• Average Net Cash Flow over 5 years is -$1.6 million, with a median of -$3.1 million recorded in 2025.
• Peak annual rise in Net Cash Flow reached 846.56% in 2023, while the deepest fall reached 16057.34% in 2023.
• Tracing ZNTL's Net Cash Flow over 5 years: stood at $518000.0 in 2022, then slumped by 16057.34% to -$82.7 million in 2023, then surged by 91.02% to -$7.4 million in 2024, then surged by 58.53% to -$3.1 million in 2025, then tumbled by 32.11% to -$4.1 million in 2026.
• The last three Net Cash Flow figures came in at -$4.1 million (Q1 2026), -$3.1 million (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.

Peer Comparison